Bremelanotide: new drug for hypoactive sexual desire disorder
Simon JA, Kingsberg SA, Portman D, et al.
Therapeutic Advances in Reproductive Health, 2019
Key finding
Comprehensive summary of bremelanotide clinical program: on-demand dosing, onset within 30-60 minutes, nausea as primary tolerability issue (40%), and favorable efficacy in HSDD.
Summary
Clinical review summarizing the full bremelanotide development program including mechanism, Phase 2 and 3 results, safety profile, and practical prescribing considerations.
Read the study
The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.
View on PubMedRelated compound
More research on PT-141
Comparison of PT-141 and Flibanserin for Female Sexual Desire Disorder: An Indirect Treatment Comparison
Sexual Medicine Reviews · 2022 · Review
Blood Pressure and Cardiovascular Effects of Bremelanotide in Hypertensive Versus Normotensive Women
Journal of Sexual Medicine · 2021 · Human RCT
Long-Term Safety and Efficacy of Bremelanotide: 1-Year Extension Study in Women with HSDD
The Journal of Sexual Medicine · 2021 · Human Pilot
RECONNECT-1: A Randomized Controlled Trial of Bremelanotide for Female Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT
RECONNECT-2: Phase 3 Trial of Bremelanotide in Premenopausal Women with Generalized Hypoactive Sexual Desire Disorder
The Journal of Sexual Medicine · 2020 · Human RCT